Pathways to improving combined modality therapy for stage III non-small cell lung cancer

Recent progress in the fields of molecular biology and immunology has improved survival for patients with advanced disease. There have also been improvements in radiotherapy including more precise targeting, modified fractionation and the use of newer beams. It is hoped that these tools can be successfully employed to better care for patients with stage III disease.

from Cancer via ola Kala on Inoreader http://ift.tt/1S884v8
via IFTTT